GDF2 and pulmonary arterial hypertension: More specifically, in PAH MVECs, BMP9 activated persistent EndMT signaling, leading to the loss of endothelial‐specific markers, gaining of mesenchymal characteristics, and decreased barrier integrity (Szulcek et al. 2020).